{"filings":[{"id":667356,"accession_number":"0001628280-26-038058","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2026-05-26T20:02:21+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Senti Biosciences issues $10M convertible notes to Celadon; discloses potential merger with $60M CVR","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$10M senior secured convertible notes sold to Celadon Partners; maturity 6 months, 12% default interest rate on event of default.","Notes convertible into common stock; mandatory exchange upon stockholder approval or CVR closing.","Potential transaction: Celadon affiliate to merge into Senti Holdings and issue CVR up to $60M tied to SENTI-202 milestones.","Company to file proxy statement for stockholder vote on potential merger and CVR issuance.","Registration rights, guarantee, and voting agreements also entered with directors and Celadon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78281,"accession_number":"0001628280-26-034834","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2026-05-14T12:48:56+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Senti Bio reports Q1 net loss $4.2M, secures up to $40M financing; FDA supports pivotal trial for SENTI-202 in R/R AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.2M ($0.14/share) vs $14.1M year ago; cash $8.9M as of March 31, 2026.","Secured up to $40M in senior secured convertible notes from Celadon Partners; initial $10M tranche expected May 2026.","FDA RMAT meeting supports single-arm multi-center pivotal trial for SENTI-202 in R/R AML after LD chemotherapy.","Donor X phenotype identified: 50% cCR (7/14) with Donor X NK cells vs 12.5% (1/8) without; longest remission 21+ months.","Lease modification gain $6.9M; cash burn reduced to $7.5M Q1 2026 from $14.1M Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96262,"accession_number":"0001628280-26-029320","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","2.03","3.02","5.01","9.01"],"status":"ready","headline":"Senti Biosciences enters $40M convertible note agreement with Celadon; initial $10M tranche","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Celadon Partners, largest stockholder, commits up to $40M via Senior Secured Convertible Notes; first tranche $10M.","Notes convertible at $0.6261/share with full-ratchet anti-dilution; maturity 6 months from closing with 200% repayment.","Upon conversion, Celadon would own 54.6% of Senti common stock, triggering a change in control.","Proceeds to fund CMC and clinical trials for SENTI-202; potential CVR transaction tied to milestones up to $60M.","Stockholder meeting required by Aug 31, 2026 to approve issuance beyond 19.99% exchange cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96260,"accession_number":"0001193125-26-177157","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K12B","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Senti Biosciences completes holding company reorganization; shares convert 1:1 to new parent SNTI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Senti Biosciences Holdings becomes new public parent; each share of old common stock converted 1:1 into new common stock.","Stock continues trading on Nasdaq under same ticker SNTI; new CUSIP 816944 102.","No change in executive officers or board of directors; same management team remains in place.","Reorganization is tax-free for shareholders; no vote required under DGCL Section 251(g).","Business, assets, and operations of the combined entity are unchanged from pre-reorganization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96261,"accession_number":"0001628280-26-022824","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Senti Biosciences to form holding company via tax-free merger; stock to trade as SNTI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holding company reorganization effective April 16, 2026 via merger into Senti Biosciences Holdings.","Each share of common stock automatically converts into one share of holding company common stock with same rights.","No stockholder vote or action required; no gain/loss recognized for U.S. federal income tax purposes.","New holding company will have same directors, officers, assets, and operations as current company.","Stock continues trading on Nasdaq under SNTI with a new CUSIP number."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110003,"accession_number":"0001628280-26-021578","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senti Bio FY2025 net loss $61.4M; SENTI-202 gets RMAT, Phase 1 data encouraging","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.4M for FY2025 ($2.73/share); Q4 loss $14.5M ($0.53/share).","Cash and equivalents $16.4M as of December 31, 2025.","SENTI-202 received RMAT designation for relapsed/refractory AML; updated Phase 1 data show encouraging responses and safety.","R&D expenses $37.6M full year; G&A expenses $26.2M full year, down in Q4 YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110002,"accession_number":"0001628280-26-019789","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Senti Biosciences cuts leased space 50% to 45,955 sq ft, amends sublease with GeneFab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leased premises reduced from ~91,910 to ~45,955 rentable sq ft effective Sept 1, 2025.","Monthly base rent for remaining space ranges $188,311 (2025-2026) to $293,010 (2032).","Landlord may draw $2.0M from existing $2.76M letter of credit; balance drops to $760,000.","Company paid or obtained payment of $1.0M reduction fee to landlord under consent amendment.","Outstanding rent of $1,374,005 from GeneFab may be satisfied via prepayment credit or cash by Sept 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126587,"accession_number":"0001628280-25-055953","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Senti Bio reports SENTI-202 Phase 1 data: 50% ORR, 42% CR/CRh at RP2D; receives FDA RMAT designation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In 18 evaluable R/R AML patients, SENTI-202 achieved 50% ORR and 42% CR/CRh at RP2D; 100% of CRs MRD negative and median duration of CR 7.6 months.","SENTI-202 was well-tolerated with no DLTs, no drug-related SAEs, and most AEs hematologic consistent with lymphodepletion.","FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202, adding to prior Orphan Drug Designation.","Logic Gate mechanism validated: selective killing of AML blasts/LSCs while sparing healthy hematopoietic stem/progenitor cells.","Company to host investor call Dec 9 at 8 AM ET; SENTI-202 potential for pivotal studies and expansion into newly diagnosed AML, pediatric AML, MDS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126586,"accession_number":"0001628280-25-052083","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senti Bio Q3 net loss $18.1M; cash $12.2M; ASH data ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $12.2M as of Sep 30, 2025, down from $48.3M at Dec 31, 2024.","Net loss $18.1M ($0.69 per share) for Q3 2025; R&D expense $10.5M, G&A $6.4M.","Phase 1 SENTI-202 in AML: updated clinical data to be presented at ASH meeting Dec 6-9, 2025.","Abstracts accepted for oral and poster presentations at ASH; company will host webcast.","No revenue; pre-commercial biotech focused on gene circuit platform for cell therapy."],"consensus_eps_estimate":-0.578,"consensus_eps_actual":-2.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143340,"accession_number":"0001854270-25-000088","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senti Bio Q2 2025 net loss $14.7M; completes dose finding for SENTI-202 AML trial, RP2D confirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.7M ($0.56 per share); cash $21.6M as of June 30, 2025, down from $48.3M at Dec 31, 2024.","Completed dose finding and confirmed RP2D for Phase 1 SENTI-202 trial in AML; now in dose expansion.","Received FDA Orphan Drug Designation for SENTI-202 in AML.","Received $1.0M from CIRM grant; added Bryan Baum to Board, Dr. James Trager to Scientific Advisory Board.","Expect additional efficacy and durability data from SENTI-202 Phase 1 study in Q4 2025."],"consensus_eps_estimate":-0.918,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143339,"accession_number":"0001854270-25-000077","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Senti Bio appoints Bryan Baum to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bryan Baum, co-founder and managing partner of K5 Global, appointed to board effective July 18, 2025.","Baum received initial option award for 43,900 shares vesting monthly over three years; annual cash retainer $35,000.","Board size increased from seven to eight members; Baum fills new seat as Class II director until 2027 annual meeting.","Baum's portfolio includes SpaceX, xAI, Anduril, OpenAI; previously sold companies Blue Vision Labs, Parrot, Operam."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161481,"accession_number":"0001854270-25-000073","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Senti Biosciences stockholders elect three Class III directors and ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Brenda Cooperstone, James Collins, and Feng Hsiung elected as Class III directors to serve until 2028 annual meeting.","Each director received over 17.3M votes for; broker non-votes ~1.2M per nominee.","KPMG LLP ratified as independent auditor for FY2025 with 18,617,895 votes for, 13,519 against, 2,887 abstain.","~71% of outstanding shares (18.6M of 26.1M) represented at the virtual annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161480,"accession_number":"0001854270-25-000069","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Senti Bio receives FDA Orphan Drug Designation for SENTI-202 CAR NK therapy in AML","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug Designation to SENTI-202 for relapsed/refractory hematologic malignancies, including AML.","SENTI-202 is a first-in-class Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy.","Phase 1 trial (NCT06325748) is ongoing; median survival for relapsed/refractory AML is 5.3 months.","Designation provides tax credits, FDA fee exemptions, and potential 7-year market exclusivity.","Approximately 20,800 new AML cases per year in the US, with 60% relapsing or dying within 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161479,"accession_number":"0001854270-25-000062","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senti Bio reports Q1 2025 net loss $14.1M; SENTI-202 Phase 1 shows 4 of 7 cCR with MRD negativity","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.1M ($1.41 per share) for Q1 2025; cash and equivalents $33.8M as of March 31.","Phase 1 SENTI-202 data: 4 of 7 patients achieved composite CR (3 CR, 1 CRh); all MRD negative by local standard of care.","Preliminary RP2D set at 1.5 x 10^9 CAR NK cells given on Days 0,7,14 in 28-day cycles after lymphodepletion.","Responses ongoing from 4+ to 8+ months; 3 patients received bone marrow transplant after SENTI-202.","R&D expenses $9.3M (up $0.5M YoY); G&A expenses $7.1M (down $0.4M YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161478,"accession_number":"0001854270-25-000046","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["2.02","8.01","7.01","9.01"],"status":"ready","headline":"SENTI-202 Phase 1 shows 5/7 ORR in R/R AML; RP2D set; cash $33.8M at Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5 of 7 evaluable R/R AML patients achieved ORR (3 CR, 1 CRh, 1 MLFS); all cCR patients MRD-negative.","No dose-limiting toxicities; preliminary RP2D set at 1.5x10^9 CAR NK cells Days 0,7,14 per 28-day cycle.","Longest ongoing response >8 months; 3 patients received bone marrow transplant after SENTI-202.","Q1 2025 preliminary: cash $33.8M, net loss $14.1M ($1.41/share); R&D $9.3M, G&A $7.1M.","SENTI-301A/SN301A HCC trial enrollment stopped due to dose-limiting toxicities; evaluating next steps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179646,"accession_number":"0001140361-25-009939","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Senti Biosciences files $300M shelf registration and enters ATM sales agreement with Leerink Partners","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Filed Form S-3 to register up to $300M of common stock, preferred, debt, warrants, and units.","Entered into ATM agreement with Leerink Partners for at-the-market sales of common stock.","Pays Leerink 3.0% commission on gross proceeds; no minimum sales obligation.","Sales may occur on Nasdaq or other trading markets; Company can suspend or terminate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179645,"accession_number":"0001854270-25-000038","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senti Bio reports Q4 net loss $0.6M; two AML patients remain in remission from SENTI-202 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $0.6M ($0.67/share); full year net loss $52.8M ($12.03/share).","SENTI-202 Phase 1: 2 of 3 AML patients achieved MRD-negative CR; both still in remission as of March 2025.","Raised $47.6M gross from PIPE in Dec 2024; net $45.1M extends cash runway into 2026.","Cash $48.3M at Dec 31, 2024; received additional $1.5M from CIRM grant in Jan 2025.","Appointed Jay Cross CFO and Faraz Siddiqui SVP Tech Ops in Feb 2025; added two board members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179644,"accession_number":"0001140361-25-007862","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Senti Biosciences appoints Feng Hsiung to board, stockholders approve 4.3M share increase in equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Feng Hsiung appointed to board as Class III director effective March 7, 2025; also joins audit committee.","Stockholders approved Amended 2022 Equity Incentive Plan adding 4,300,000 shares and extending term to 2035.","Board adopted Amended Inducement Plan reserving extra 500,000 shares for new-hire inducement grants.","Non-employee director compensation policy revised; each continuing director received 43,900-share option grant.","CEO Timothy Lu received contingent option for 1,927,073 shares and RSU for 642,358 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179643,"accession_number":"0001140361-25-007658","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Senti Biosciences stockholders approve share issuance and amended equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved issuance of common stock upon conversion of Series A preferred and exercise of warrants (2,442,111 for, 125,063 against).","Approved Amended and Restated 2022 Equity Incentive Plan (2,196,615 for, 371,748 against).","Approved adjournment to solicit additional proxies if needed (2,258,129 for).","Equity plan adds 4,816,434 shares plus annual 5% evergreen increase through 2034."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179642,"accession_number":"0001854270-25-000008","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Senti Bio appoints Jay Cross as CFO and Faraz Siddiqui as SVP Technical Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jay Cross appointed CFO effective March 3, 2025; base salary $465k, annual target bonus 40%, sign-on bonus $50k repayable if leaving before 14 months.","Stock option for 174,200 shares (or 44,000 if stockholder proposal fails) under 2022 Inducement Plan; four-year vesting.","Faraz Siddiqui joined as SVP Technical Operations in Jan 2025; oversees manufacturing, supply chain; previously at IGM Biosciences, Instil Bio, Kite Pharma, Genentech.","CEO Timothy Lu served as interim principal financial officer from Jan 31 until 10-K filing when Cross assumes role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179641,"accession_number":"0001628280-25-004293","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Senti Biosciences CFO Yvonne Li departs; transition consultant through March 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yvonne Li's consulting agreement as Interim CFO expired Jan 31, 2025; she ceased as principal financial and accounting officer.","Entered new consulting agreement on Feb 5, 2025 for transition support until March 31, 2025.","No permanent CFO appointment announced; Li will cooperate with executive management on orderly handover."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179640,"accession_number":"0001140361-25-000337","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["2.03","8.01","3.02","9.01"],"status":"ready","headline":"Senti Bio secures additional $11.5M from PIPE closing and CIRM grant; cash runway into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed subsequent PIPE closing with Celadon Partners for additional ~$10M gross proceeds (4,444 Series A shares + warrants for 6,666,000 common shares); total PIPE now $47.6M.","Received $1.5M from CIRM grant; total received $6.4M of $8M grant announced June 2024.","Cash runway guidance extended into 2026; proceeds to fund SENTI-202 development and manufacturing.","Securities sold under Section 4(a)(2)/Rule 506 exemption; registration rights agreement for resale filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196382,"accession_number":"0001854270-24-000128","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Senti Bio doses first patient in SN301A CAR-NK trial for liver cancer in China","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in SN301A pilot trial for advanced GPC3-expressing HCC in mainland China.","SN301A is SENTI-301A CAR-NK product candidate manufactured and developed by Celest Therapeutics.","Open-label, single-center study (NCT06652243) evaluating safety, pharmacokinetics, and anti-tumor activity.","Three dose levels administered in 28-day cycles with lymphodepletion conditioning.","Over 40% of global HCC cases occur in China; Senti retains rights outside Greater China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196381,"accession_number":"0001140361-24-048293","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Senti Biosciences releases initial Phase 1 clinical data for SENTI-202; no specific results disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Initial clinical data from Phase 1 trial of SENTI-202 made available in slide presentation deck.","Data reported under Item 8.01; no specific numeric results or interim analyses provided in the 8-K body.","Company cautions forward-looking statements; risks include clinical trial uncertainties.","Stock ticker SNTI; filing date December 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196380,"accession_number":"0001140361-24-048184","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","5.03","2.03","3.02","3.03","5.02","8.01","9.01"],"status":"ready","headline":"Senti Biosciences raises up to $47.6M in Series A preferred stock and warrants private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued up to 21,157 shares of Series A Convertible Preferred at $2,250/share, with warrants for up to 31.7M common shares at $2.30.","Initial closing of $37.6M (16,713 preferred shares) expected Dec 5, 2024; option for additional $9.9M by Dec 27, 2024.","Series A Preferred carries 18% annual cumulative dividend, convertible into common at $2.25 after stockholder approval.","Director Omid Farokhzad resigned; Frances Schulz (former EY partner) and Donald Tang (Celadon designee) appointed to board.","Net proceeds to fund working capital, R&D, and SENTI-202 program advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196379,"accession_number":"0001140361-24-048114","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Senti Bio reports 2 of 3 AML patients achieve MRD-negative CR in Phase 1 SENTI-202 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two of three R/R AML patients at lowest dose (1.0B CAR+ NK cells) achieved CR with MRD negativity; both maintain remission (4+ and 3+ months).","SENTI-202 was generally well-tolerated with no DLTs; adverse events consistent with lymphodepleting chemotherapy and other investigational NK therapies.","Dose escalation continues at 1.5B cells/dose level; additional safety, efficacy and durability data expected in 2025.","SENTI-202 transgene detected in peripheral circulation of all patients across cycles, with PK profile similar to other CAR-NK therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196378,"accession_number":"0001854270-24-000114","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senti Bio Q3 net loss $28.9M; cash $10.5M; SENTI-202 data expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.9M ($6.31 per share); R&D spend $8.7M (down from $9.1M YoY).","Cash and equivalents $10.5M at Sept 30; subsequent $2.5M CIRM tranche received.","Phase 1 enrollment of SENTI-202 ongoing; initial safety/efficacy data on track by year-end.","CIRM grant total $8.0M; $4.9M received through Nov 2024.","SENTI-301A pilot trial with Celest expects first patient dosing in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196377,"accession_number":"0001854270-24-000108","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Senti Bio receives Nasdaq deficiency notice for audit committee composition","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Oct 22, 2024, Nasdaq notified Senti Bio that its audit committee has only two members, violating Listing Rule 5605(c)(2)(A).","Vacancy resulted from Susan Berland’s resignation from the board effective June 11, 2024.","Cure period: until Dec 9, 2024 (since next annual meeting already held) or June 11, 2025, whichever earlier.","No immediate impact on listing or trading of SNTI common stock on Nasdaq Capital Market.","Company evaluating committee membership and intends to regain compliance before cure deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212690,"accession_number":"0001854270-24-000105","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Senti subleases 7,247 RSF of HQ to BKPBIOTECH/JLSA2 Therapeutics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublease of 7,247 rentable sq ft on first floor at Two Corporate Drive, South San Francisco.","Term effective October 1, 2024 through April 30, 2027, subject to landlord consent.","Initial monthly base rent $35,147.95, escalating to $36,378.13 (Y2) and $37,651.36 (Y3).","Subtenant is jointly and severally BKPBIOTECH, Inc. and JLSA2 Therapeutics, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212689,"accession_number":"0001854270-24-000099","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Senti Bio Q2 net loss $11.2M; doses first patients in Phase 1 AML trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.2M ($2.45 per share) for Q2 2024; cash and equivalents $15.9M.","R&D expenses rose to $9.2M (vs $6.9M YoY) on increased manufacturing costs.","Phase 1 trial of SENTI-202 for AML now dosing; initial efficacy data expected by year-end 2024.","Received $8M CIRM grant to support SENTI-202 clinical development.","Regained Nasdaq minimum bid price compliance after 1-for-10 reverse stock split in July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212688,"accession_number":"0001854270-24-000094","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Senti Biosciences effectuates 1-for-10 reverse stock split effective July 17, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio approved by Board on July 10, 2024.","Effective 5:00 p.m. ET on July 17, 2024; trading on split-adjusted basis begins July 18 under symbol SNTI.","No fractional shares issued; cash payment in lieu at July 17 closing price.","Authorized shares and par value remain unchanged; new CUSIP is 81726A209.","Reverse split intended to maintain Nasdaq listing compliance; proportional adjustments to equity awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212687,"accession_number":"0001854270-24-000091","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Senti Biosciences amends ChEF purchase agreement to allow intraday VWAP share sales under $50M facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered amended ChEF purchase agreement with Chardan Capital Markets for existing $50M equity facility.","Amendment permits intraday volume-weighted average price (VWAP) purchases of common stock.","The change gives the company flexibility to sell shares more frequently under the facility.","Shares sold under the agreement are restricted securities and resale registered under Registration Rights Agreement.","The Agreement amends and restates the original August 31, 2022 ChEF Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212686,"accession_number":"0001854270-24-000081","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["3.03","5.07","5.03","9.01"],"status":"ready","headline":"Senti Biosciences shareholders approve officer exculpation and reverse stock split authorization (range 1:5 to 1:30)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved an officer exculpation amendment limiting liability of certain officers as permitted by Delaware law; effective July 10, 2024.","Reverse stock split approved at ratio between 1:5 and 1:30, as determined by the Board; Board may abandon the split.","KPMG LLP ratified as independent auditor for fiscal year ending Dec 31, 2024 (30,547,655 votes for, 63,495 against).","Officer exculpation amendment and reverse split were Proposals 2 and 3; 68.97% of outstanding shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231713,"accession_number":"0001854270-24-000061","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Senti Bio appoints Kanya Rajangam as President; CEO Lu remains CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tim Lu stepped down as President effective May 14, 2024, but continues as CEO.","Kanya Rajangam, M.D., Ph.D., appointed President; she remains Head of R&D and CMO.","Rajangam joined Senti in July 2022; prior CMO at Nkarta (NKTX) and Atara (ATRA).","Her compensation includes $490K base salary, 40% target bonus, option grant, and severance per 2022 offer letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231712,"accession_number":"0001854270-24-000050","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senti Bio Q1 net loss $12.1M; SENTI-202 patient dosing on track for Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $23.7M at March 31, 2024; additional $18.9M receivable from GeneFab.","Net loss $12.1M ($0.26 per share); R&D expenses rose to $8.8M from $7.1M on manufacturing costs.","SENTI-202 Phase 1 trial for AML on track to dose first patient in Q2 2024; initial efficacy data by year-end 2024.","Pilot trial of SENTI-301A for HCC in China (Celest partnership) expects first patient dosing in Q2 2024.","Presented three abstracts at ASGCT 2024, including novel CAR discovery and engineered synthetic switches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231711,"accession_number":"0001854270-24-000041","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Senti Biosciences appoints Yvonne Li Interim CFO; CEO Lu named interim PFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Lu, CEO/President, becomes interim principal financial & accounting officer effective May 4, 2024.","Yvonne Li appointed Interim CFO effective May 4, 2024; will become principal financial & accounting officer after Q1 10-Q filing.","Li consulting agreement: $350/hour, max aggregate payment of $370,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231710,"accession_number":"0001854270-24-000036","cik":1854270,"company_name":"Senti Biosciences, Inc.","ticker":"SNTI","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Senti Bio CFO Deborah Knobelman resigns; search for interim CFO underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deborah Knobelman, Ph.D., CFO, Treasurer and Head of Corp. Dev., resigned effective May 3, 2024.","Resignation not due to any disagreement with the company on operations, policies, or practices.","Company entered consulting agreement with Knobelman effective May 4, 2024, for transition; max payment $60,000.","Company has initiated search to identify an interim CFO and treasurer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31144754.455445547,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}